ANI Pharmaceuticals (BSFA) Ownership - Who Owns ANI Pharmaceuticals?
ANI Pharmaceuticals (BSFA) Ownership Overview
- 7.75% Insiders
- 20.99% Mutual Funds
- 1.46% Other Institutional Investors
- 28.26% ETFs
- 41.54% Public Companies and Individual Investors
The ownership structure of ANI Pharmaceuticals (DE:BSFA) stock is a mix of institutional, retail, and individual investors. Approximately 50.71% of the company’s stock is owned by Institutional Investors, 7.75% is owned by Insiders, and 41.54% is owned by Public Companies and Individual Investors.
The ownership structure of ANI Pharmaceuticals (DE:BSFA) stock is a mix of institutional, retail, and individual investors. Approximately 50.71% of the company’s stock is owned by Institutional Investors, 7.75% is owned by Insiders, and 41.54% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Aug 10, 2026 | Ori Gutwerg | $243,474 | |
| May 12, 2026 | Nikhil Lalwani | $4,266,350 | |
| May 12, 2026 | Thomas Andrew Rowland | $36,357 | |
| May 12, 2026 | Ori Gutwerg | $220,374 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Graham Capital Management, L.p. | €466,298 | |
| Dec 31, 2025 | Hussman Strategic Advisors Inc | €2,486,610 | |
| Dec 31, 2025 | Hotchkis & Wiley Capital Management Llc | €5,903,133 | |
| Dec 31, 2025 | Driehaus Capital Management Llc | €6,013,649 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Ishares | 2,301,940 | Institution | 10.03% | 166,375,015 |
| Vanguard | 1,185,948 | Institution | 5.17% | 85,715,578 |
| Avantis | 921,982 | Institution | 4.02% | 66,637,171 |
| Vanguard Index Funds | 818,536 | Institution | 3.57% | 59,160,508 |
| Ivy Funds | 724,412 | Institution | 3.16% | 52,357,602 |
| Steven A. Tananbaum | 667,981 | Institution | 2.91% | 48,278,995 |
| Muthusamy Shanmugam | 537,976 | Insider | 2.34% | 38,882,753 |
| Spdr | 505,884 | Institution | 2.20% | 36,563,272 |
| Dfa | 471,032 | Institution | 2.05% | 34,044,309 |
| Nikhil Lalwani | 333,689 | Insider | 1.45% | 24,117,706 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 818,536 | Institution | 3.57% | 59,160,508 |
| Ivy Funds | 724,412 | Institution | 3.16% | 52,357,602 |
| Dfa Investment Dimensions Group Inc | 297,076 | Institution | 1.29% | 21,471,465 |
| Fidelity Salem Street Trust | 246,188 | Institution | 1.07% | 17,793,484 |
| Tiaa-cref Funds | 202,352 | Institution | 0.88% | 14,625,193 |
| Fidelity Concord Street Trust | 188,472 | Institution | 0.82% | 13,622,002 |
| Nuveen Investment Funds, Inc. | 157,111 | Institution | 0.68% | 11,355,355 |
| Vanguard Scottsdale Funds | 141,888 | Institution | 0.62% | 10,255,097 |
| Schwab Capital Trust | 140,404 | Institution | 0.61% | 10,147,840 |
| Columbia Funds Series Trust I | 139,524 | Institution | 0.61% | 10,084,237 |
FAQ
Who Owns ANI Pharmaceuticals (DE:BSFA)?
According to the latest TipRanks data, approximately 50.71% of the company's stock is held by institutional investors, 7.75% is held by insiders, and 41.54% is held by public companies and individual investors.
What percentage of ANI Pharmaceuticals (DE:BSFA) stock is held by institutional investors?
According to the latest TipRanks data, approximately 50.71% of ANI Pharmaceuticals (DE:BSFA) stock is held by institutional investors: 20.99% by mutual funds, 28.26% by ETFs and 1.46% by other institutional investors.
What percentage of ANI Pharmaceuticals (DE:BSFA) stock is held by retail investors?
According to the latest TipRanks data, approximately 41.54% of ANI Pharmaceuticals (DE:BSFA) stock is held by public companies and individual investors.
Who owns the most shares of ANI Pharmaceuticals (DE:BSFA)?
iShares owns the most shares of ANI Pharmaceuticals (DE:BSFA).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.